Adeflo Capsules Dosing
For adult patients with asthma, Adeflo capsules (salmeterol 50 µg + fluticasone propionate 250 µg or 500 µg) should be administered as one inhalation twice daily, approximately 12 hours apart, with the specific strength selected based on asthma severity and prior inhaled corticosteroid use.
Dosage Selection Algorithm
Starting dose determination:
Patients NOT currently on inhaled corticosteroids (ICS): Start with the lower strength combination (50 µg salmeterol + 250 µg fluticasone propionate) twice daily 1
Patients already on ICS or with greater asthma severity: Select from available strengths based on current ICS dose:
- Low-medium dose ICS users: 50/250 µg twice daily
- High-dose ICS users or poorly controlled patients: 50/500 µg twice daily 1
Maximum dose: Do not exceed 50/500 µg twice daily 1
Administration Instructions
- Administer via oral inhalation twice daily (morning and evening, approximately 12 hours apart)
- Rinse mouth with water without swallowing after each inhalation to reduce local side effects like oral candidiasis 1
- Do not use with a spacer or volume-holding chamber 1
- Never exceed two inhalations per 24-hour period 1
Dose Adjustment Strategy
After initiating therapy:
- Improvement typically occurs within 15 minutes, but maximum benefit may take 1 week or longer 1
- If inadequate control after 2 weeks, consider increasing to the next higher strength 1
- Once asthma stability is achieved, titrate down to the lowest effective dose to minimize adverse effects 1
- If a previously effective regimen fails, reassess compliance, inhaler technique, and consider additional controller therapies rather than simply increasing the dose 1
Critical Safety Considerations
Long-acting beta-agonists (LABAs) like salmeterol carry important warnings:
- LABAs should never be used as monotherapy for asthma—they must always be combined with an ICS 2
- There have been concerns about increased severe exacerbations and deaths when LABAs are added to usual asthma therapy, prompting FDA warnings 2
- However, recent evidence in children showed that salmeterol combined with fluticasone in fixed-dose combination had similar safety to fluticasone alone 3
Common pitfalls to avoid:
- Do not use for acute bronchospasm relief—this requires a short-acting beta-agonist 1
- Avoid concomitant use of other LABAs 1
- If short-acting beta-agonist use increases to more than 2 days per week (excluding exercise-induced bronchospasm prevention), this indicates inadequate control requiring treatment escalation 2
Guideline Context
The NAEPP guidelines position combination ICS/LABA therapy at Step 3 and higher for asthma management, with low-dose ICS plus LABA as the preferred option for Step 3, and medium-to-high dose ICS plus LABA for Steps 4-6 2. The fluticasone/salmeterol combination provides both anti-inflammatory and bronchodilator effects in a single device, improving adherence 4.